V

Vaccinex
D

VCNX

3.63000
USD
0.03
(0.83%)
مغلق
حجم التداول
0
الربح لكل سهم
-0
العائد الربحي
-
P/E
0
حجم السوق
9,716,192
أصول ذات صلة
    AZN
    AZN
    -1.830
    (-2.81%)
    65.635 USD
    B
    BNTX
    -3.740
    (-3.61%)
    99.740 USD
    C
    CVM
    0.00010
    (0.02%)
    0.56020 USD
    I
    INO
    -0.54000
    (-11.25%)
    4.26000 USD
    JNJ
    JNJ
    2.140
    (1.41%)
    155.14 USD
    MRK
    MRK
    -2.050
    (-2.08%)
    99.16 USD
    MRNA
    MRNA
    -2.950
    (-7.42%)
    36.830 USD
    N
    NVAX
    0.12000
    (1.67%)
    7.32500 USD
    PFE
    PFE
    -1.225
    (-4.71%)
    25.63 USD
    V
    VXRT
    -0.05030
    (-7.97%)
    0.58050 USD
    المزيد
الأخبار

العنوان: Vaccinex

القطاع: Healthcare
الصناعة: Biotechnology
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.